This is an open-label Phase 1 study to estimate the safety and manufacturing feasibility of
lentivirally transduced T cells expressing anti-CD38 chimeric antigen receptors expressing
tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in patients with Acute Myeloid
Leukemia and Multiple Myeloma. This CAR T cell product will be referred to as "CART-38
cells".